EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have […]

Final Prospectus

As filed with the Securities and Exchange Commission

CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering

CM Life Sciences III Inc. (the “Company”) announced today that it priced its initial public offering of 48,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “CMLTU” beginning April 7, 2021.